Upcoming AWS Coverage on Vertex Pharmaceuticals

LONDON, UK / ACCESSWIRE / March 29, 2017 / Active Wall St. blog coverage looks at the headline from Cara Therapeutics, Inc. (NASDAQ: CARA) as the Company announced on March 28, 2017, positive top-line results from Part A of its Phase-2/3 trial. The trial demonstrated that I.V. CR845 met both primary and secondary endpoints for efficacy (reducing itchiness and improving quality of life, respectively) in patients with uremic pruritus (UP). Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Cara Therapeutics’ competitors within the Biotechnology space, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), is estimated to report earnings on April 26, 2017. AWS will be initiating a research report on Vertex Pharma following the release of its next earnings results.

Today, AWS is promoting its blog coverage on CARA; touching on VRTX. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

UP is a debilitating systemic itch condition with a high prevalence in patients with chronic kidney disease (CKD), for which there are no approved therapies in the United States.

“We are extremely pleased with these results, where I.V. CR845 demonstrated sustained clinical and quality of life benefits in dialysis patients suffering from UP and supports the viability of this therapeutic approach for the long-term treatment of this unmet medical need,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics, “As a next step, we plan to meet with the FDA to finalize the trial design of Part B of this Phase-2/3 study and to initiate patient recruitment later this year.”

I.V. CR845 Phase 2/3 UP Trial Design and Top-line Results

Part A of the Phase-2/3 UP trial was a randomized, double-blind, placebo-controlled trial of three doses of I.V. CR845 administered three times per week after dialysis over an eight-week treatment period in 174 patients with moderate-to-severe UP.

The primary endpoint was the change from baseline of the mean worst itching score for week eight based on a validated 0-10 Numeric Rating Scale. Patients receiving I.V. CR845 experienced a 68 percent greater reduction from baseline in worst itch scores than those receiving placebo.

The secondary endpoint focused on quality of life measures associated with pruritus using the Skindex-10 score, a validated self-assessment scale with higher scores indicating worse quality of life. Patients receiving I.V. CR845 experienced a 100% greater reduction from baseline in the average total Skindex-10 score at week eight than those receiving placebo. The total average Skindex-10 score reflected statistically significant reductions in each of the three Skindex-10 domains.

Cara Therapeutics plans to meet with the US Food and Drug Administration (FDA) for an end-of-Phase-2 meeting to review the results to determine an optimal dose to take into Part B of this Phase-2/3 study, and define the broader path towards approval. Pending discussions with the FDA, Part B of the study is intended to be a randomized, double-blind, placebo-controlled trial of I.V. CR845 administered three times per week after dialysis over a 12-week treatment period in up to 240 patients with moderate-to-severe UP.

Stock Performance

On Tuesday, March 28, 2017, following the announcement, the stock closed the trading session at $19.09, jumping 5.18% from its previous closing price of $18.15. A total volume of 7.63 million shares have exchanged hands, which was higher than the 3-month average volume of 1.81 million shares. Cara Therapeutics’ stock price soared 17.77% in the last month, 91.47% in the past three months, and 146.32% in the previous six months. Furthermore, on a year to date basis, the stock surged 105.49%. At Tuesday’s closing price, the stock’s net capitalization stands at $519.06 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458432

Upcoming AWS Coverage on Ryder System Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 29, 2017 / Active Wall St. blog coverage looks at the headline from Rent-A-Center, Inc. (NASDAQ: RCII) as the Company announced on March 28, 2017, that its Board of Directors has unanimously adopted a stockholder rights plan to protect the best interests of all Rent-A-Center’s stockholders. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Rent-A-Center’s competitors within the Rental & Leasing Services space, Ryder System, Inc. (NYSE: R), announced on March 25, 2017, that its management will review first quarter results on April 25, 2017, at 11:00 a.m. ET. AWS will be initiating a research report on Ryder System in the coming days.

Today, AWS is promoting its blog coverage on RCII; touching on R. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Rights Plan

According to the announcement, the Rights Plan is designed to protect Rent-A-Center’s stockholders by reducing the stakes of an event where any person or group holds the control of the Company through open market accumulation, without offering appropriate compensation to its stockholders for such control, or offering the Board of Directors ample time to make reasonable judgment.

The Rights will become exercisable if a person or group becomes the beneficial owner of 15% or more of the outstanding Common Stock of the Company. The Rights is additionally exercisable in case the entity announces a tender offer for 15% or more of the outstanding Common Stock of the Company. In the event, when the Rights become exercisable, each Right will entitle its holder to purchase at the Right’s exercise price, a number of shares of Common Stock or equivalent securities with a market value at that time of twice the Right’s exercise price.

The Power Shift

This announcement comes in the light of the recent resignation of Robert D. Davis, CEO, and Director, Rent-A-Center on January 09, 2017. Board Chairman Mark E. Speese, the Company’s founder, and former CEO, took over as interim CEO. Post this management transition, Rent-A-Center confirmed that Engaged Capital, LLC, has provided notice of intent to nominate five individuals to stand for the three available positions up for elections to the Board of Directors, on February 23, 2017.

Engaged Capital LLC, holds 12.9% stake in Rent-A-Center and has expressed its interest to acquire the Company which has been struggling with declining sales for over a year. The activist fund, however, disapproved Rent-A-Center’s ‘risky’ turnaround strategy and urged the Company to consider other options.

Rent-A-Center’s Announcement

On February 14, 2017, Rent-A-Center announced decisive and immediate actions to drive improvement and deliver greater value in the long-term. The Company announced several measures including achievement of optimal product mix by shifting to an upper concentration of the higher-end, and providing a better value proposition while being more customer-centric. The Company probably plans to minimize costs and boost revenues after directions from Engaged Capital on the retailer to explore an acquisition.

February Key Operating Metrics

Rent-A-Center recently reported key operating metrics for its Core US and Acceptance NOW businesses on for February 2017 on March 16, 2017. The Company reported that its Core US business observed sales to decrease continuously owing to drop in merchandise sales revenue from the tax refund delay.

The average monthly rate of new agreements declined by 4.1% in February FY17 compared to February, FY16. The co-worker turnover, however, advanced by 75.6% and 14.7% in February FY17 for the Core US business. The store sales for the Automotive Segment declined 3.8% y-o-y in February FY16. The merchandise sales had dipped by 15% in February FY16 which caused delay in tax refunds, thus eventually leading to sales depreciation.

Rent-A-Center, a rent-to-own industry leader based in Texas, operates approximately 2,600 stores in the US, Mexico, Canada and Puerto Rico with an additional 1,870 Acceptance Now kiosk locations in the US and Puerto Rico.

The Rights Plan has an expiration date of March 28, 2020, or earlier if stockholder approval of the Rights Plan has not been obtained, or prior to Rent-A-Center’s 2018 Annual Meeting of Stockholders.

Stock Performance

At the close of trading session on Tuesday, March 28, 2017, Rent-A-Center’s stock price slightly rose by 0.33% to end the day at $9.10. A total volume of 1.01 million shares were exchanged during the session. The Company’s share price has gained 4.60% in the past one month. The stock currently has a market cap of $476.39 million and has a dividend yield of 3.52%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458424

Upcoming AWS Coverage on Live Nation Entertainment Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 29, 2017 / Active Wall St. blog coverage looks at the headline from IMAX Corp. (NYSE: IMAX) as the Company announced and Warner Bros. Home Entertainment, a subsidiary of Time Warner, Inc. (NYSE: TWX) announced collectively on March 28, 2017, a new virtual reality (VR) co-financing and production agreement to develop and release three interactive and exclusive VR experiences. The highly anticipated titles include Justice League, Aquaman, and the third title, which is yet to be announced. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of IMAX’s competitors within the Entertainment – Diversified space, Live Nation Entertainment, Inc. (NYSE: LYV), released its financial results for the three and twelve months ended December 31, 2016, on February 23, 2017. AWS will be initiating a research report on Live Nation Entertainment in the coming days.

Today, AWS is promoting its blog coverage on IMAX and TWX; touching on LYV. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Details of the Agreement

The IMAX VR Experience features a unique combination of premium technology and world-class content, enabling the users to see, feel, move, and play in a different environment. The centers featuring the VR Experience will be located in multiplexes, malls, and other commercial and standalone destinations while using a modular design, proprietary to IMAX. The design consists of multiple pods to allow multiple players to enjoy unique VR Experiences. The pods are designed to enhance user mobility and interaction in virtual environments and hence can be adapted for specific content experiences.

The Companies plan to launch one experience, each year, beginning with Justice League VR in Q4 FY17 where each title will receive an exclusive window in IMAX VR centers probably before the title is released for other VR platforms, including in-home and mobile offerings.

IMAX VR Developments

On November 10, 2016, IMAX Corp., and IMAX China Holding collectively announced that the Companies had completed the first phase of a $50 million virtual reality fund midst IMAX and other strategic investors, hence assisting the completion of at least 25 VR content experiences over the next three years. IMAX announced that it was in the process of launching its first pilot IMAX VR centers in Los Angeles and at ODEON & UCI Cinemas Group’s Printworks multiplex location in England.

IMAX announced the launch of first pilot IMAX VR center in Europe with an intent to deliver immersive and multi-dimensional VR experiences to users. IMAX eventually plans to incorporate premium content resulting from a cinema-grade virtual reality camera, currently under development in a partnership with Google.

At the beginning of this year, IMAX opened the doors of its first VR Centre across the grove in Los Angeles. To date, approximately 15,000 admissions have been clocked on this venue with five more centers scheduled to open this year in New York, California, Shanghai, and the UK.

IMAX Growth Portfolio

IMAX has been holding a sustainable growth portfolio for long now. It recently extended its long-standing relationship with Walt Disney Studios, a division of The Walt Disney Company where the Companies collectively announced that they had extended their multi-faceted agreement with a new multi-picture deal. Under terms of the agreement, both Companies will work together to create exclusive IMAX marketing materials to eventually deliver unmatched entertainment.

The Company recently reported its full-year FY16 results on February 23, 2017. The Company signed agreements for a record 238 new theaters in 2016, which was double the previous two years combined. IMAX installed 117 new theater systems, representing a 56% increase from FY15.

Stock Performance

On Tuesday, March 28, 2017, the stock closed the trading session at $34.00, slightly down 0.29% from its previous closing price of $34.10. A total volume of 660.28 thousand shares have exchanged hands. IMAX’s stock price surged 9.32% in the last three months, 15.65% in the past six months, and 9.22% in the previous twelve months. Moreover, the stock gained 8.28% since the start of the year. At Tuesday’s closing price, the stock’s net capitalization stands at $2.25 billion. The stock is currently trading at a P/E ratio of 80.76.

Yesterday, Time Warner’s stock ended the trading session at $97.32, declining slightly by 0.04% from its previous close of $97.36. A total volume of 2.71 million shares was exchanged. The stock has advanced 1.36% in the last three months, 28.98% in the last six months and 37.37% since last 12 months. Moreover, the stock has gained 1.24% since the start of the year. The net market capital for the Company was $75.10 billion as per its Tuesday’s closing price. The stock is trading at a P/E ratio of 19.64 and has a dividend yield of 1.65%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458435

Fans of the Eye Revitalizing Cream can Learn more about the Innovative Product as well as Read Articles on Skincare on the New Page

LOS ANGELES, CA / ACCESSWIRE / March 29, 2017 / The founders of Allure RX, a skincare cream that is designed to treat the delicate skin around the eyes, are pleased to announce the launch of their Facebook page.

To check out the new page, “like” it and learn more about the company and Allure RX, please visit https://www.facebook.com/AllureRX/ at any time.

As a company spokesperson noted, the Facebook page will not only include updates about Allure RX and information about the eye revitalizer; it will also feature numerous helpful articles with tips about skincare and related topics.

Even though the Facebook page was just recently launched, two recent posts – one on the basics of healthy skincare and one on how people can achieve better skin at every age – are already popular with people who have visited the social media site.

The page also features photos of women who have used Allure RX; as the saying goes, when it comes to showing how well the eye revitalizer works, a picture is worth a thousand words.

Because the skin around the eyes is extremely thin, the spokesperson said, it can be especially vulnerable to aging and exposure to external factors. These can cause issues like dark circles, wrinkles and puffiness to take hold, which in turn can make the eyes look tired and dull.

“AllureRX Eye Revitalizer may give the delicate skin cells beneath your eyes the nutrient support they need to radically rebuild and rejuvenate,” the spokesperson said, adding that with each application, it may help tone and tighten the skin in the under-eye region and smooth away crow’s feet, which may result in youthful clarity and vibrancy as the cells rejuvenate.

“The Eye Revitalizer has been formulated with a blend of ingredients that includes active skin firming peptides, herbal extracts and botanicals. These ingredients may work synergistically to support under-eye skin health, improve visual appearance and even boost skin immunity.”

For example, grape extract is a key ingredient in Allure RX; it is a natural antioxidant that may help protect the skin around the eyes from the damaging rays of the sun. The cream also contains aloe vera gel – which is known to help soothe the skin – vitamin K and passion flower extract.

About Allure RX:

Made with skin firming peptides, Allure RX is a specialty eye revitalizer helping to improve elasticity, tone, and texture in the under-eye region. For more information on Allure RX please visit https://www.allure-rx.com.

Contact:

David Harper
admin@rocketfactor.com
(949) 555-2861

SOURCE: Allure RX

ReleaseID: 458456

Enertopia Announces Lithium Carbonate Purity Testing Underway

VANCOUVER, BC / ACCESSWIRE / March 29, 2017 / Enertopia Corporation (OTCQB: ENRT; CSE: TOP) (the “Company” or “Enertopia”) is pleased to announce that it has been notified by the 3rd party laboratory that the Lithium Carbonate purity testing is underway on the four Lithium carbonate samples recently produced from the Genesis Water Technologies (GWT) bench tests. The third party laboratory is using Ion Chromatography to determine the precise purity in the submitted four Lithium carbonate samples.

The Company has expedited the time for testing the samples and believes it will have the purity results within two weeks.

Since the Company’s press release of the bench test recovery numbers on March 6, 2017, it has received several requests for further information from Lithium producers and other leaders in the Lithium space.

Enertopia looks forward to the results of the 3rd party independent laboratory testing to determine the purity of lithium carbonate product produced from processing of the 4 brine samples by GWTs recovery process. Once these results have been received and reviewed by Enertopia and GWT, Enertopia will provide the outline for the next phase of development and selection process for the pilot plant location.

“Modern technology is revolutionizing Lithium production technology, and potentially providing a much better way to recover lithium, while protecting our environment. We are enthusiastic in becoming leaders in this evolution,” stated President and CEO, Robert McAllister.

About Enertopia

Enertopia is exploring a portfolio of three prospective lithium projects in Nevada and reviewing other mineral projects, while concurrently working with water purification technology partner GWT using patent pending technology that is believed able to recover Lithium from brine solutions.

Enertopia shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com, or call Robert McAllister, the President, at 1.250.765.6412.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its health and wellness, mining projects, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements, foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. There can be no assurance that the brine recovery system will be effective for the recovery of Lithium and if effective will be economic or have any positive impact on Enertopia. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

SOURCE: Enertopia Corporation

ReleaseID: 458399

The New Page is Already Popular with Fans of the Advanced Wrinkle Moisturizer

LOS ANGELES, CA / ACCESSWIRE / March 29, 2017 / The founders of SkinFresh MD, a company that makes an Advanced Wrinkle Moisturizer that is designed to naturally combat the aging process, are pleased to announce the creation and launch of their Facebook page.

To check out the new Facebook page and learn more about SkinFresh MD Advanced Wrinkle Moisturizer and how it works to naturally reduce the appearance of wrinkles, please visit https://www.facebook.com/SkinFreshMD/
at any time.

As a company spokesperson noted, the new Facebook page will also include plenty of posts related to skincare; for example, an article titled “20 Skincare Tips Every Woman Should Know” is already creating a buzz with visitors to the page, as is a post that describes seven ways people age 50 and over can save their skin.

To get the latest updates from SkinFresh MD, people simply need to “like” the new Facebook page; they may also post stories and photos of how the skincare cream has helped them.

“SkinFreshMD may help in the regeneration of healthy skin cells at a cellular level to improve overall skin health,” the spokesperson noted, adding that the secret to SkinFresh MD’s ability to help nourish and rejuvenate the skin is in its list of ingredients.

“SkinFreshMD combines active skin firming peptides, soothing herbal extracts and botanicals which may work synergistically to reduce the most stubborn visible signs of aging and may support overall skin health and appearance.”

For example, SkinFresh MD contains an Argireline Complex that includes Acetyl Hexapeptide-8, a skin firming peptide that can offer dermal facial contouring to restore elasticity. The skincare cream also includes vitamin C, a rich source of ascorbic acid. As the spokesperson noted, ascorbic acid has been found to work synergistically with the other active ingredients in the formula to boost the skin’s ability to trap and retain moisture, enhancing hydration and nourishment.

Aloe vera gel, avocado oil and cucumis sativus are also found in SkinFresh MD Advanced Wrinkle Moisturizer, along with hydrolyzed soy protein, which may help improve the health of skin that is being negatively impacted by hormonal issues.

Using SkinFresh MD is easy – after washing their faces with a gentle cleanser and patting the skin dry, people simply need to smooth on the SkinFreshMD Advanced Wrinkle Moisturizer cream across the face and allow time for it to absorb.

About SkinFresh MD:

SkinFresh MD Advanced Wrinkle Moisturizer is formulated with active and effective ingredients that work to combat the skin’s aging process. For more information please visit https://www.skinfreshmd.com.

Contact:

Aubrey Vega

admin@rocketfactor.com
(949) 555-2861

SOURCE: SkinFresh MD

ReleaseID: 458447